Consolidating unified interests for improved cancer care can enhance efficiency and quality of care for patients, said Tracy Bahl, MBA, president and chief executive officer of OneOncology.
Consolidating unified interests for improved cancer care can enhance efficiency and quality of care for patients, said Tracy Bahl, MBA, president and chief executive officer of OneOncology.
Transcript
What best practices have emerged for surviving in a market that is seeing more and more consolidation?
Consolidation historically has existed in this almost adversarial context. We have to consolidate as much mass as possible so that we can pit ourselves against, competitively, the rest of the marketplace—so that we can bring greater leverage and greater power in the marketplace. In the end, that kind of consolidation only furthers the adversary relationship that has broken the American healthcare system. Instead, consolidation in the context of something like OneOncology, is designed to bring those economies of scale and economies of intelligence that enable us to align our interest with others who are equally motivated to improve cancer care in their community. So, we get better data, better analytics, and greater affordability for others—whether they be payers, whether they be hospitals, whether they be other community oncology practices or other physicians that share the same mission we do. We can bring that together in a consolidated way and drive greater efficiency and better patient care.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More